133 related articles for article (PubMed ID: 2110134)
1. Prediction from creatinine clearance of thrombocytopenia and recommended dose in patients receiving (glycolato-O,O')-diammine platinum (II) (NSC 375101D).
Sasaki Y; Fukuda M; Morita M; Shinkai T; Eguchi K; Tamura T; Ohe Y; Yamada K; Kojima A; Nakagawa K
Jpn J Cancer Res; 1990 Feb; 81(2):196-200. PubMed ID: 2110134
[TBL] [Abstract][Full Text] [Related]
2. Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion.
Sasaki Y; Amano T; Morita M; Shinkai T; Eguchi K; Tamura T; Ohe Y; Kojima A; Saijo N
Cancer Res; 1991 Mar; 51(5):1472-7. PubMed ID: 1997185
[TBL] [Abstract][Full Text] [Related]
3. Prediction of hematologic toxicity of carboplatin by creatinine clearance rate.
Taguchi J; Saijo N; Miura K; Shinkai T; Eguchi K; Sasaki Y; Tamura T; Sakurai M; Minato K; Fujiwara Y
Jpn J Cancer Res; 1987 Sep; 78(9):977-82. PubMed ID: 3117753
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of carboplatin in recurrent ovarian cancer: severe hematologic toxicity in previously treated patients.
Colombo N; Speyer JL; Green M; Canetta R; Beller U; Wernz JC; Meyers M; Widman T; Blum RH; Piccart M
Cancer Chemother Pharmacol; 1989; 23(5):323-8. PubMed ID: 2650904
[TBL] [Abstract][Full Text] [Related]
5. Phase I clinical trial and pharmacokinetics of carboplatin (NSC 241240) by single monthly 30-minute infusion.
Koeller JM; Trump DL; Tutsch KD; Earhart RH; Davis TE; Tormey DC
Cancer; 1986 Jan; 57(2):222-5. PubMed ID: 3510700
[TBL] [Abstract][Full Text] [Related]
6. A phase I trial of cis-diammine-1,1-cyclobutane dicarboxylate platinum II (Carboplatin, CBDCA, JM-8) with a single dose every five week-schedule.
Joss RA; Kaplan S; Goldhirsch A; Sessa C; Brunner KW; Cavalli F
Invest New Drugs; 1984; 2(3):297-304. PubMed ID: 6392147
[TBL] [Abstract][Full Text] [Related]
7. [Phase I study of a new platinum complex 254-S, cis-diammine (glycolato)-platinum (II)].
Ota K; Wakui A; Majima H; Niitani H; Inuyama Y; Ogawa M; Ariyoshi Y; Yoshida O; Taguchi T; Kimura I
Gan To Kagaku Ryoho; 1992 Jun; 19(6):855-61. PubMed ID: 1605663
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of 1,2-diamminomethyl-cyclobutane-platinum (II)-lactate (D-19466; lobaplatin) administered daily for 5 days.
Gietema JA; de Vries EG; Sleijfer DT; Willemse PH; Guchelaar HJ; Uges DR; Aulenbacher P; Voegeli R; Mulder NH
Br J Cancer; 1993 Feb; 67(2):396-401. PubMed ID: 8431374
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function.
Egorin MJ; Van Echo DA; Tipping SJ; Olman EA; Whitacre MY; Thompson BW; Aisner J
Cancer Res; 1984 Nov; 44(11):5432-8. PubMed ID: 6386150
[TBL] [Abstract][Full Text] [Related]
10. A dose-finding and pharmacokinetic study of nedaplatin in elderly patients with advanced non-small cell lung cancer.
Yamamoto N; Tamura T; Kurata T; Yamamoto N; Sekine I; Kunitoh H; Ohe Y; Saijo N
Cancer Chemother Pharmacol; 2009 Dec; 65(1):79-88. PubMed ID: 19396598
[TBL] [Abstract][Full Text] [Related]
11. Phase I clinical and pharmacokinetic study of an one-hour infusion of ormaplatin (NSC 363812).
Tutsch KD; Arzoomanian RZ; Alberti D; Tombes MB; Feierabend C; Robins HI; Spriggs DR; Wilding G
Invest New Drugs; 1999; 17(1):63-72. PubMed ID: 10555124
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of (glycolate-0,0')-diammine platinum (II), a new platinum derivative, in comparison with cisplatin and carboplatin.
Sasaki Y; Tamura T; Eguchi K; Shinkai T; Fujiwara Y; Fukuda M; Ohe Y; Bungo M; Horichi N; Niimi S
Cancer Chemother Pharmacol; 1989; 23(4):243-6. PubMed ID: 2647312
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function.
Welink J; Boven E; Vermorken JB; Gall HE; van der Vijgh WJ
Clin Cancer Res; 1999 Sep; 5(9):2349-58. PubMed ID: 10499604
[TBL] [Abstract][Full Text] [Related]
14. [Analysis of Nedaplatin Dose in Patients with Impaired Renal Function].
Araki R; Iwamizu H; Kataoka T; Kumakura Y; Miyazaki M; Nagai T; Ando Y; Yamada K
Gan To Kagaku Ryoho; 2017 Feb; 44(2):143-147. PubMed ID: 28223671
[TBL] [Abstract][Full Text] [Related]
15. Phase I and pharmacokinetic study of the novel platinum analogue CI-973 on a 5-daily dose schedule.
O'Dwyer PJ; Hudes GR; Walczak J; Schilder R; LaCreta F; Rogers B; Cohen I; Kowal C; Whitfield L; Boyd RA
Cancer Res; 1992 Dec; 52(24):6746-53. PubMed ID: 1458462
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of cis-dichloro-trans-dihydroxy-bis(isopropylamine)platinum IV (CHIP).
Ribaud P; Gouveia J; Misset JL; Mathé G
Oncology; 1986; 43(2):78-82. PubMed ID: 3951788
[TBL] [Abstract][Full Text] [Related]
17. [A phase II clinical study of cis-diammine glycolato platinum, 254-S, for cervical cancer of the uterus].
Noda K; Ikeda M; Yakushiji M; Nishimura H; Terashima Y; Sasaki H; Hata T; Kuramoto H; Tanaka K; Takahashi T
Gan To Kagaku Ryoho; 1992 Jun; 19(6):885-92. PubMed ID: 1605666
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacological approach to the platinum compounds].
Sasaki Y
Gan To Kagaku Ryoho; 1992 Apr; 19(4):456-62. PubMed ID: 1313667
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of (glycolate-O,O') diammineplatinum(II), a novel platinum complex, in the treatment of non-small-cell lung cancer.
Fukuda M; Shinkai T; Eguchi K; Sasaki Y; Tamura T; Ohe Y; Kojima A; Oshita F; Hara K; Saijo N
Cancer Chemother Pharmacol; 1990; 26(6):393-6. PubMed ID: 2171794
[TBL] [Abstract][Full Text] [Related]
20. A novel pharmacodynamically based approach to dose optimization of carboplatin when used in combination with etoposide.
Belani CP; Egorin MJ; Abrams JS; Hiponia D; Eisenberger M; Aisner J; Van Echo DA
J Clin Oncol; 1989 Dec; 7(12):1896-902. PubMed ID: 2555452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]